Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1755-1762

  Park, S ^a,b   Koo, J S ^a,b   Kim, M S ^b,c   Park, H S ^a   Lee, J S ^a,a   Kim, S I ^a,b   Park, B W ^a,b   Lee, K S ^d  

^a Yonsei University College of Medicine   (South Korea)

^b Target Molecule Study Group   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d CHA University   (South Korea)

Author keywords

Androgen receptor; Breast cancer; Estrogen receptor; Molecular apocrine; Prognosis

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 79960989401     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq678     Document Type: Article

References (28)

1. Moe RE, Anderson BO. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 2007; 95: 437-439.
2. Higgins MJ, Wolff AC. The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat 2010; 124: 619-621.
3. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010; 21: 488-492.
4. Schippinger W, Regitnig P, Dandachi N et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 2006; 449: 24-30.
5. Castellano I, Allia E, Accortanzo V et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010; 124: 607-617.
6. Agoff SN, Swanson PE, Linden H et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003; 120: 725-731.
7. Gucalp A, Traina TA. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010; 16: 62-65.
8. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol 2008; 4: 15-21.
9. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007; 105: 1-15.
10. Page JH, Colditz GA, Rifai N et al. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1032-1036.
11. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
12. Beekman KW, Hussain M. Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urol Oncol 2008; 26: 415-419.
13. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-4671.
14. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
15. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008; 10: 542-548.
16. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
17. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010; 120: 293-308.
18. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003; 98: 703-711.
19. Ogawa Y, Hai E, Matsumoto K et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008; 13: 431-435.
20. Niemeier LA, Dabbs DJ, Beriwal S et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-212.
21. Peters AA, Buchanan G, Ricciardelli C et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69: 6131-6140.
22. Macedo LF, Guo Z, Tilghman SL et al. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006; 66: 7775-7782.
23. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2009; 2: 59.
24. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997; 193: 753-758.
25. Putti TC, El-Rehim DM, Rakha EA et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005; 18: 26-35.
26. Bhargava R, Beriwal S, Striebel JM, Dabbs DJ. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol 2010; 18: 113-118.
27. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005; 105: 3352-3370.
28. Traina TA, Feigin K, Patil S et al. Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer. Presented at IMPAKT Annual Meeting, 7-9 May 2009, Brussels, Belgium. Ann Oncol 2009; 20: ii63-ii64.